TAM September 2018 CME Posttest

The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:

September 2018, Volume 26, Issue 3

Overview

• CME Credit Available: 3.25 AMA PRA Category 1 Credits™
• Release Date: September 28, 2018
• Expiration Date: September 28, 2019

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, the learner will be able to:

• Describe the impact of microbiota on HIV infection
• Answer predominant questions about HIV-related opportunistic infections, including issues such as prophylaxis, polymerase chain reaction–based diagnostics, and likely updates to guidelines
• Implement strategies for prevention and treatment of human papillomavirus–related cancers in individuals with HIV infection
• Describe the effects of and potential treatments for opioid use disorders in individuals with HIV infection

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV infection.

Intended Audience

This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and HCV infections.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from September 28, 2018, to September 28, 2019. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Dr Schooley has served as a consultant to CytoDyn, Pfizer, and Vir Biotechnology. He has received grant support from Gilead Sciences, Inc, and holds stock or stock options in Antiva Biosciences and CytoDyn. His spouse serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 09/12/18)

Dr Masur has no relevant financial affiliations to disclose. (Updated 09/19/18)

Dr Wilkin has served as a consultant to GlaxoSmithKline/ViiV Healthcare, and has received grant support, paid to his institution, from GlaxoSmithKline/ViiV Healthcare. His spouse owns stock in Johnson & Johnson. (Updated 09/17/18)

Dr Bruce has no relevant financial affiliations to disclose. (Updated 09/11/18)

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 09/26/18)

The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

Independent educational grants for the 2018 Improving the Management of HIV Disease® CME program:

PLATINUM SUPPORTERS
Gilead Sciences, Inc
ViiV Healthcare

SILVER SUPPORTERS
Janssen Therapeutics
Merck

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

Email: journal“at”iasusa.org
Mail: 425 California St, Ste 1450, San Francisco, CA 94104-2120
Phone: (415) 544-9400
Fax: (415) 544-9401

By clicking the link below, I acknowledge that I have read these instructions and understand them.